$569 Million is the total value of Fairmount Funds Management LLC's 27 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 14.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | Buy | AXSOME THERAPEUTICS INC | $84,628,000 | +134.4% | 1,896,647 | +101.2% | 14.88% | +80.1% |
| COGT | COGENT BIOSCIENCES INC | $41,164,000 | +65.4% | 2,758,975 | 0.0% | 7.24% | +27.0% | |
| Buy | NUVALENT INC | $40,433,000 | +73.8% | 2,079,863 | +21.2% | 7.11% | +33.5% | |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $32,043,000 | -9.4% | 2,543,107 | -23.9% | 5.63% | -30.4% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO | $30,951,000 | -19.6% | 204,743 | -22.5% | 5.44% | -38.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $30,057,000 | +9.0% | 283,000 | 0.0% | 5.28% | -16.3% | |
| INSM | Buy | INSMED INC | $28,785,000 | +10.1% | 1,336,368 | +0.8% | 5.06% | -15.5% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $28,091,000 | +157.2% | 1,369,623 | +45.1% | 4.94% | +97.5% |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $27,379,000 | +605.3% | 2,678,982 | +189.1% | 4.81% | +442.0% |
| New | AXSOME THERAPEUTICS INCcall | $26,772,000 | – | 600,000 | +100.0% | 4.71% | – | |
| ARGX | ARGENX SEsponsored adr | $25,958,000 | -6.8% | 73,526 | 0.0% | 4.56% | -28.4% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $24,341,000 | +9.7% | 469,264 | 0.0% | 4.28% | -15.7% | |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $21,906,000 | +75.4% | 2,833,950 | +54.5% | 3.85% | +34.7% |
| ANNX | Buy | ANNEXON INC | $20,756,000 | +90.3% | 3,358,563 | +16.1% | 3.65% | +46.2% |
| DBVT | Buy | DBV TECHNOLOGIES SAsponsored adr | $12,505,000 | +1.5% | 7,064,964 | +46.2% | 2.20% | -22.0% |
| TYRA BIOSCIENCES INC | $12,455,000 | +22.9% | 1,416,998 | 0.0% | 2.19% | -5.6% | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $12,300,000 | +16.1% | 751,804 | 0.0% | 2.16% | -10.8% | |
| TERN | New | TERNS PHARMACEUTICALS INC | $12,075,000 | – | 2,050,000 | +100.0% | 2.12% | – |
| BGNE | Sell | BEIGENE LTDsponsored adr | $11,648,000 | -35.4% | 86,400 | -22.4% | 2.05% | -50.4% |
| KROS | KEROS THERAPEUTICS INC | $10,251,000 | +36.2% | 272,498 | 0.0% | 1.80% | +4.6% | |
| TRVI | Buy | TREVI THERAPEUTICS INC | $8,773,000 | +92.2% | 5,696,515 | +250.7% | 1.54% | +47.6% |
| ASTRIA THERAPEUTICS INC | $8,242,000 | +201.4% | 911,736 | 0.0% | 1.45% | +131.5% | ||
| AMRN | AMARIN CORP PLCspons adr new | $6,087,000 | -26.8% | 5,584,837 | 0.0% | 1.07% | -43.8% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $3,732,000 | -13.2% | 389,588 | 0.0% | 0.66% | -33.3% | |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $3,399,000 | -68.7% | 1,231,566 | -53.9% | 0.60% | -76.0% |
| TIL | INSTIL BIO INC | $3,262,000 | +4.8% | 673,905 | 0.0% | 0.57% | -19.5% | |
| ALLK | ALLAKOS INC | $901,000 | +95.4% | 147,189 | 0.0% | 0.16% | +49.1% | |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -2,245,891 | -100.0% | -3.07% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -953,396 | -100.0% | -6.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.